First AD

Second AD

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events and prophylaxis strategies.

Treatment Considerations With Regorafenib in Colorectal Cancer

Colorectal Cancer

ELI-22-OSD1261 - /clinical/colorectal-cancer

 Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Insights

Insights is an expert interview video series of leading oncologists that provides in-depth reports and feature segments profiling leaders in a range of oncology disciplines, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecologic cancers, and hematologic malignancies. Most episodes feature 2 clinicians discussing the latest oncology advances in clinical practice. 

Adverse Event Management in Colorectal Cancer: Optimizing Treatment Approaches in the 3L Setting

The University of Texas MD Anderson Cancer Center

Cancer Centers

Partner

Focusing on the treatment of patients receiving regorafenib, the panel details the management of common adverse events, prophylaxis strategies, and the roles of members within a multidisciplinary team.

Selecting Optimal 3L Colorectal Cancer Treatment

Patient Case 1: 46-Year-Old Woman with Prior Hx of MSS pT4aN1b Rectosigmoid Colon Adenocarcinoma s/p Prior Treatment

General Approach to 3L CRC Treatment with TAS-102 + Bevacizumab

Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC

Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer

Patient Case 3: A 57-Year-Old Man With Cecal Colon Adenocarcinoma

FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC

Monitoring and AE Management Strategies with Fruquintinib in CRC

Toxicity Considerations and Treatment Decisions in CRC

Multidisciplinary Care for Patients with CRC

Unmet Needs and Future Perspectives in Colorectal Cancer